{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T16:07:08Z","timestamp":1762358828856,"version":"build-2065373602"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100023448","name":"Robert Koch-Institut","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100023448","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>HIV and HCV share similar routes of infection. Individuals carrying both viruses experience a faster progression of the liver disease. We have analyzed people with new HIV-1 diagnoses in Germany for active or resolved HCV infection for over ten years. The time period covers the introduction of direct acting antivirals (DAA), a paradigmatic shift in HCV therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A central component of the HIV surveillance in Germany is the notification of new diagnoses. Residual blood samples from 16,539 people with new HIV-1 diagnoses reported between 2009 and 2019 were examined for HCV antigen and\/or antibodies. Reactive cases were further investigated for active or resolved HCV infection by RT-qPCR. The results were analyzed with socio-demographic information from the notification forms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study includes samples from 48.0% of all notified HIV-1 diagnoses. The seroprevalence of cases with HCV antigen, antibodies or both, representing active and resolved infections was 6.2% with stable seroprevalence. The average proportion of resolved infections among those was 33.0% with a significant increase since the introduction of DAAs in 2012 (p\n                      <jats:sub>Trend_2012-2019<\/jats:sub>\n                      \u2009=\u20090.028) reaching 48.2% in 2019. The highest proportion of active and resolved cases (73.7%) was found in people who inject drugs (PWIDs). This transmission group had the lowest percentage of resolved infections with 29.4%. The proportion of active and resolved cases in persons with heterosexual mode of transmission (HET) and in men who have sex with men (MSM) was 3.8% and 2.6%, respectively. The peak percentage of resolved infections was found in MSM (40.0%), followed by HET (36.6%). The proportion of active and resolved cases among individuals with non-German origin was higher than in people with German origin (8.8%, versus 4.3%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and the proportion of resolved HCV infections lower (27.8% versus 34.0%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.027).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The proportion of resolved HCV infections among people newly diagnosed with HIV-1 increased after the introduction of DAAs in Germany. The high prevalence and the low proportion of resolved HCV infections reveal that unmet diagnostic and therapeutic needs exist among PWIDs. The higher proportion of active and resolved cases among individuals of non-German origin particularly requires greater public health attention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-025-12025-8","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:34:16Z","timestamp":1762353256000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Active and resolved HCV infections among people with new HIV-1 diagnoses in Germany, 2009\u20132019"],"prefix":"10.1186","volume":"25","author":[{"given":"Daniel","family":"Ivanusic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amare","family":"Eshetu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hussein","family":"Al-Shehabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrycja","family":"Klink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Koppe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Gunsenheimer-Bartmeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviane","family":"Bremer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Bannert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"12025_CR1","unstructured":"Global hepatitis report 2024: action for access in low- and middle-income countries. 2024. Geneva: World Health Organization. Available from https:\/\/iris.who.int\/bitstream\/handle\/10665\/376461\/9789240091672-eng.pdf?sequence=1"},{"key":"12025_CR2","unstructured":"Epidemiological fact sheet, hiv statistics, globally and by who region, 2023. Available from: https:\/\/cdn.who.int\/media\/docs\/default-source\/hq-hiv-hepatitis-and-stis-library\/j0294-who-hiv-epi-factsheet-v7.pdf"},{"issue":"1","key":"12025_CR3","doi-asserted-by":"publisher","first-page":"28586","DOI":"10.1038\/s41598-024-80289-2","volume":"14","author":"D Zarebska-Michaluk","year":"2024","unstructured":"Zarebska-Michaluk D, Rzymski P, Kanecki K, Tyszko P, Lewtak K, Gorynski P, Genowska A, Parczewski M, Flisiak R. Hospitalizations and deaths among people coinfected with HIV and HCV. Sci Rep. 2024;14(1):28586","journal-title":"Sci Rep"},{"issue":"7","key":"12025_CR4","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S1473-3099(15)00485-5","volume":"16","author":"L Platt","year":"2016","unstructured":"Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C, Yanny I, Razavi H, Vickerman P. Prevalence and burden of HCV co-infection in people living with hiv: a global systematic review and meta-analysis. Lancet Infect Dis. 2016;16(7):797\u2013808","journal-title":"Lancet Infect Dis"},{"issue":"7156","key":"12025_CR5","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1136\/bmj.317.7156.424","volume":"317","author":"RA Coutinho","year":"1998","unstructured":"Coutinho RA. Hiv and hepatitis C among injecting drug users. BMJ. 1998;317(7156):424\u201325","journal-title":"BMJ"},{"issue":"6","key":"12025_CR6","doi-asserted-by":"publisher","first-page":"e25348","DOI":"10.1002\/jia2.25348","volume":"22","author":"BM Nijmeijer","year":"2019","unstructured":"Nijmeijer BM, Koopsen J, Schinkel J, Prins M, Geijtenbeek TB. Sexually transmitted hepatitis C virus infections: current trends, and recent advances in understanding the spread in men who have sex with men. J Int AIDS Soc. 2019;22 Suppl 6):e25348","journal-title":"J Int AIDS Soc"},{"issue":"6","key":"12025_CR7","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1086\/515315","volume":"177","author":"DL Thomas","year":"1998","unstructured":"Thomas DL, Villano SA, Riester KA, Hershow R, Mofenson LM, Landesman SH, Hollinger FB, Davenny K, Riley L, Diaz C, et al. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and infants transmission study. The J Infect Dis. 1998;177(6):1480\u201388","journal-title":"The J Infect Dis"},{"key":"12025_CR8","doi-asserted-by":"publisher","first-page":"726419","DOI":"10.3389\/fimmu.2021.726419","volume":"12","author":"ST Gobran","year":"2021","unstructured":"Gobran ST, Ancuta P, Shoukry NH. A tale of two viruses: immunological insights into HCV\/HIV coinfection. Front Immunol. 2021;12:726419","journal-title":"Front Immunol"},{"issue":"17","key":"12025_CR9","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1097\/QAD.0000000000000834","volume":"29","author":"H Hagan","year":"2015","unstructured":"Hagan H, Jordan AE, Neurer J, Cleland CM. Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men. Aids. 2015;29(17):2335\u201345","journal-title":"Aids"},{"issue":"7","key":"12025_CR10","doi-asserted-by":"publisher","first-page":"e2203","DOI":"10.1093\/cid\/ciaa1113","volume":"73","author":"JK Rockstroh","year":"2021","unstructured":"Rockstroh JK. Hepatitis C micro-elimination in human Immunodeficiency virus-Coinfected men Who have Sex with men: a low hanging fruit? Clin Infect Dis. 2021;73(7):e2203\u2013e 2204","journal-title":"Clin Infect Dis"},{"issue":"4","key":"12025_CR11","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3748\/wjg.v25.i4.398","volume":"25","author":"M Ganesan","year":"2019","unstructured":"Ganesan M, Poluektova LY, Kharbanda KK, Osna NA. Human immunodeficiency virus and hepatotropic viruses co-morbidities as the inducers of liver injury progression. World J Gastroenterol. 2019;25(4):398\u2013410","journal-title":"World J Gastroenterol"},{"issue":"6","key":"12025_CR12","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nrgastro.2014.17","volume":"11","author":"JY Chen","year":"2014","unstructured":"Chen JY, Feeney ER, Chung RT. HCV and HIV co-infection: mechanisms and management. Nat Rev Gastroenterol Hepatol. 2014;11(6):362\u201371","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"12025_CR13","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1086\/603557","volume":"49","author":"d\u2019Arminio Monforte A","year":"2009","unstructured":"d\u2019Arminio Monforte A, Cozzi-Lepri A, Castagna A, Antinori A, De Luca A, Mussini C, Caputo SL, Arlotti M, Magnani G, Pellizzer G, et al. Risk of developing specific AIDS-defining illnesses in patients coinfected with hiv and hepatitis C virus with or without liver cirrhosis. Clin Infect Dis. 2009;49(4):612\u201322","journal-title":"Clin Infect Dis"},{"issue":"3","key":"12025_CR14","doi-asserted-by":"publisher","first-page":"e0173943","DOI":"10.1371\/journal.pone.0173943","volume":"12","author":"N Rallon","year":"2017","unstructured":"Rallon N, Garcia M, Garcia-Samaniego J, Rodriguez N, Cabello A, Restrepo C, Alvarez B, Garcia R, Gorgolas M, Benito JM. HCV coinfection contributes to hiv pathogenesis by increasing immune exhaustion in CD8 T-cells. PLoS One. 2017;12(3):e0173943","journal-title":"PLoS One"},{"issue":"1","key":"12025_CR15","doi-asserted-by":"publisher","first-page":"5606","DOI":"10.1038\/s41598-019-41788-9","volume":"9","author":"MR Lopez-Huertas","year":"2019","unstructured":"Lopez-Huertas MR, Palladino C, Garrido-Arquero M, Esteban-Cartelle B, Sanchez-Carrillo M, Martinez-Roman P, Martin-Carbonero L, Ryan P, Dominguez-Dominguez L, Santos IL, et al. HCV-coinfection is related to an increased HIV-1 reservoir size in cART-treated hiv patients: a cross-sectional study. Sci Rep. 2019;9(1):5606","journal-title":"Sci Rep"},{"issue":"3","key":"12025_CR16","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1080\/15284336.2017.1330801","volume":"18","author":"K Neukam","year":"2017","unstructured":"Neukam K, Morano-Amado LE, Rivero-Juarez A, Mancebo M, Granados R, Tellez F, Collado A, Rios MJ, de Los Santos-Gil I, Reus-Banuls S, et al. HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study. HIV Clin Trials. 2017;18(3):126\u201334","journal-title":"HIV Clin Trials"},{"issue":"3","key":"12025_CR17","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/hep.30400","volume":"70","author":"D Salmon-Ceron","year":"2019","unstructured":"Salmon-Ceron D, Nahon P, Layese R, Bourcier V, Sogni P, Bani-Sadr F, Audureau E, Merchadou L, Dabis F, Wittkop L, et al. Human immunodeficiency virus\/Hepatitis C virus (HCV) Co-infected patients with cirrhosis are No longer at higher risk for hepatocellular carcinoma or end-stage liver disease as compared to HCV mono-infected patients. Hepatology. 2019;70(3):939\u201354","journal-title":"Hepatology"},{"issue":"11","key":"12025_CR18","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1007\/s10620-018-5215-0","volume":"63","author":"C Sikavi","year":"2018","unstructured":"Sikavi C, Najarian L, Saab S. Similar sustained virologic response in real-world and clinical trial studies of hepatitis C\/Human immunodeficiency virus coinfection. Dig Dis Sci. 2018;63(11):2829\u201339","journal-title":"Dig Dis Sci"},{"key":"12025_CR19","unstructured":"United Nations General Assembly. Transforming our world: the 2030 agenda for sustainable development general Assembly resolution A\/RES\/70\/1: United Nations general Assembly. 2015. Available from https:\/\/www.un.org\/en\/development\/desa\/population\/migration\/generalassembly\/docs\/globalcompact\/A_RES_70_1_E.pdf"},{"key":"12025_CR20","unstructured":"Bundesministerium f\u00fcr Gesundheit, Bundesministerium f\u00fcr wirtschaftliche Zusammenarbeit und Entwicklung. Strategie zur Eind\u00e4mmung von HIV, Hepatitis B und C und anderen sexuell \u00fcbertragbaren Infektionen. Bis 2030 - Bedarfsorientiert \u00b7 Integriert \u00b7 Sektor\u00fcbergreifend. Bundesministerium f\u00fcr Gesundheit. 2016. Available from https:\/\/www.bundesgesundheitsministerium.de\/fileadmin\/Dateien\/5_Publikationen\/Praevention\/Broschueren\/Strategie_BIS_2030_HIV_HEP_STI.pdf"},{"issue":"27\u201328","key":"12025_CR21","first-page":"479","volume":"120","author":"U Fiebig","year":"2023","unstructured":"Fiebig U, Altmann B, Hauser A, Koppe U, Hanke K, Gunsenheimer-Bartmeyer B, Bremer V, Baumgarten A, Bannert N. Primary resistance of viruses in reported New cases of hiv, 2017-2020. Dtsch Arztebl Int. 2023;120(27\u201328):479\u201380","journal-title":"Dtsch Arztebl Int"},{"key":"12025_CR22","doi-asserted-by":"crossref","unstructured":"Hauser A, Hofmann A, Hanke K, Bremer V, Bartmeyer B, Kuecherer C, Bannert N National molecular surveillance of recently acquired HIV infections in Germany & comma; 2013 to 2014. Euro Surveill. 2017;22(2)","DOI":"10.2807\/1560-7917.ES.2017.22.2.30436"},{"issue":"1","key":"12025_CR23","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1186\/s12879-017-2585-4","volume":"17","author":"A Hofmann","year":"2017","unstructured":"Hofmann A, Hauser A, Zimmermann R, Santos-Hovener C, Batzing-Feigenbaum J, Wildner S, Kucherer C, Bannert N, Hamouda O, Bremer V, et al. Surveillance of recent hiv infections among newly diagnosed hiv cases in Germany between 2008 and 2014. BMC Infect Dis. 2017;17(1):484","journal-title":"BMC Infect Dis"},{"key":"12025_CR24","doi-asserted-by":"publisher","first-page":"113839","DOI":"10.1016\/j.jviromet.2020.113839","volume":"279","author":"A Eshetu","year":"2020","unstructured":"Eshetu A, Hauser A, Schmidt D, Bartmeyer B, Bremer V, Obermeier M, Ehret R, Volkwein A, Bock CT, Bannert N. Comparison of two immunoassays for concurrent detection of HCV antigen and antibodies among HIV\/HCV co-infected patients in dried serum\/plasma spots. J Virol Methods. 2020;279:113839","journal-title":"J Virol Methods"},{"issue":"1","key":"12025_CR25","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12985-019-1135-7","volume":"16","author":"B Wang","year":"2019","unstructured":"Wang B, Kruger L, Machnowska P, Eshetu A, Gunsenheimer-Bartmeyer B, Bremer V, Hauser A, Bannert N, Bock CT. Characterization of a hepatitis C virus genotype 1 divergent isolate from an HIV-1 coinfected individual in Germany assigned to a new subtype 1o. Virol J. 2019;16(1):28","journal-title":"Virol J"},{"key":"12025_CR26","unstructured":"SurvStat@RKI 2.0. Available from. https:\/\/survstat.rki.de\/Default.aspx. Accessed September 15th 2020"},{"issue":"1","key":"12025_CR27","doi-asserted-by":"publisher","first-page":"e0116975","DOI":"10.1371\/journal.pone.0116975","volume":"10","author":"F Rouet","year":"2015","unstructured":"Rouet F, Deleplancque L, Mboumba BB, Sica J, Mouinga-Ondeme A, Liegeois F, Goudeau A, Dubois F, Gaudy-Graffin C. Usefulness of a fourth generation elisa assay for the reliable identification of HCV infection in HIV-positive adults from Gabon (Central Africa). PLoS One. 2015;10(1):e0116975","journal-title":"PLoS One"},{"issue":"1","key":"12025_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S2468-1253(20)30303-4","volume":"6","author":"F Jin","year":"2021","unstructured":"Jin F, Dore GJ, Matthews G, Luhmann N, Macdonald V, Bajis S, Baggaley R, Mathers B, Verster A, Grulich AE. Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(1):39\u201356","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"12025_CR29","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s12954-024-01119-2","volume":"21","author":"G Steffen","year":"2024","unstructured":"Steffen G, Krings A, Guttmann S, Lubke N, Meyer-Schlinkmann K, Tiemann C, Timm J, Walker A, Zimmermann R. Group Ds: progress and challenges in the elimination of hepatitis C among people who inject drugs in Germany: results of a pilot study for a national monitoring system, 10 years after the first data collection. Harm Reduct J. 2024;21(1):222","journal-title":"Harm Reduct J"},{"issue":"5\u20136","key":"12025_CR30","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00103-013-1673-x","volume":"56","author":"C Poethko-Muller","year":"2013","unstructured":"Poethko-Muller C, Zimmermann R, Hamouda O, Faber M, Stark K, Ross RS. Thamm M: [Epidemiology of hepatitis a, B, and C among adults in Germany: results of the German health interview and examination survey for adults (DEGS1)]. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz. 2013;56(5\u20136):707\u201315","journal-title":"Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz"},{"key":"12025_CR31","doi-asserted-by":"crossref","unstructured":"Rantala M, van de Laar MJ. Surveillance and epidemiology of hepatitis B and C in Europe - a review. Euro Surveill. 2008;13(21)","DOI":"10.2807\/ese.13.21.18880-en"},{"key":"12025_CR32","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3389\/fpubh.2020.00424","volume":"8","author":"I Sperle","year":"2020","unstructured":"Sperle I, Steffen G, Leendertz SA, Sarma N, Beermann S, Thamm R, Simeonova Y, Cornberg M, Wedemeyer H, Bremer V, et al. Prevalence of hepatitis B, C, and D in Germany: results from a scoping review. Front Public Health. 2020;8:424","journal-title":"Front Public Health"},{"key":"12025_CR33","first-page":"3","volume":"47","author":"A der Heiden M Mu","year":"2021","unstructured":"der Heiden M Mu A, Kollan C, Schmidt D, Gunsenheimer-Bartmeyer B BV. Sch\u00e4tzung der Zahl der HIV-Neuinfektionen und der Gesamtzahl von Menschen mit HIV in Deutschland, Stand Ende 2020. Epid Bull. 2021;47:3\u201317","journal-title":"Epid Bull"},{"key":"12025_CR34","doi-asserted-by":"publisher","first-page":"100792","DOI":"10.1016\/j.lanepe.2023.100792","volume":"36","author":"C Thomadakis","year":"2024","unstructured":"Thomadakis C, Gountas I, Duffell E, Gountas K, Bluemel B, Seyler T, Pericoli FM, Kaszoni-Ruckerl I, El-Khatib Z, Busch M, et al. Prevalence of chronic HCV infection in EU\/EEA countries in 2019 using multiparameter evidence synthesis. Lancet Reg Health Eur. 2024;36:100792","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"12025_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jhep.2017.01.024","volume":"67","author":"R Zimmermann","year":"2017","unstructured":"Zimmermann R, Kollan C, Ingiliz P, Mauss S, Schmidt D, Bremer V. Real-world treatment for chronic hepatitis C infection in Germany: analyses from drug prescription data, 2010-2015. J Hepatol. 2017;67(1):15\u201322","journal-title":"J Hepatol"},{"issue":"6","key":"12025_CR36","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/jvh.13670","volume":"29","author":"A Krings","year":"2022","unstructured":"Krings A, Schmidt D, Meixenberger K, Bannert N, Munstermann D, Tiemann C, Kollan C, Gunsenheimer-Bartmeyer B. Decreasing prevalence and stagnating incidence of hepatitis C-co-infection among a cohort of HIV-1-positive patients, with a majority of men who have sex with men, in Germany, 1996-2019. J Viral Hepat. 2022;29(6):465\u201373","journal-title":"J Viral Hepat"},{"issue":"1","key":"12025_CR37","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/hep.26639","volume":"59","author":"J Grebely","year":"2014","unstructured":"Grebely J, Page K, Sacks-Davis R, van der Loeff MS, Rice TM, Bruneau J, Morris MD, Hajarizadeh B, Amin J, Cox AL, et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology. 2014;59(1):109\u201320","journal-title":"Hepatology"},{"issue":"2","key":"12025_CR38","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/hiv.13554","volume":"25","author":"A Krings","year":"2024","unstructured":"Krings A, Schmidt D, Kollan C, Meixenberger K, Bannert N, Munstermann D, Tiemann C, Bremer V, Gunsenheimer-Bartmeyer B, Hivssg G. Increasing hepatitis B vaccination coverage and decreasing hepatitis B co-infection prevalence among people with HIV-1 in Germany, 1996-2019. Results from a cohort study primarily in men who have sex with men. HIV Med. 2024;25(2):201\u201311","journal-title":"HIV Med"},{"issue":"11","key":"12025_CR39","doi-asserted-by":"publisher","first-page":"e0142515","DOI":"10.1371\/journal.pone.0142515","volume":"10","author":"K Jansen","year":"2015","unstructured":"Jansen K, Thamm M, Bock CT, Scheufele R, Kucherer C, Muenstermann D, Hagedorn HJ, Jessen H, Dupke S, Hamouda O, et al. High prevalence and high incidence of coinfection with hepatitis B, hepatitis C, and syphilis and low rate of effective vaccination against hepatitis B in HIV-Positive men Who have Sex with men with known date of hiv seroconversion in Germany. PLoS One. 2015;10(11):e0142515","journal-title":"PLoS One"},{"key":"12025_CR40","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/1471-2334-11-132","volume":"11","author":"AJ Schmidt","year":"2011","unstructured":"Schmidt AJ, Marcus U. Self-reported history of sexually transmissible infections (STIs) and STI-related utilization of the German health care system by men who have sex with men: data from a large convenience sample. BMC Infect Dis. 2011;11:132","journal-title":"BMC Infect Dis"},{"issue":"7","key":"12025_CR41","doi-asserted-by":"publisher","first-page":"100701","DOI":"10.1016\/j.jhepr.2023.100701","volume":"5","author":"C Graf","year":"2023","unstructured":"Graf C, Fuhrmann L, Lutz T, Stephan C, Knecht G, Gute P, Bickel M, Peiffer KH, Finkelmeier F, Dultz G, et al. Expanding epidemic of recently acquired HCV in HIV-coinfected patients over a period of 10 years. JHEP Rep. 2023;5(7):100701","journal-title":"JHEP Rep"},{"issue":"6","key":"12025_CR42","doi-asserted-by":"publisher","first-page":"e414","DOI":"10.1016\/S2352-3018(22)00077-7","volume":"9","author":"S Hosseini-Hooshyar","year":"2022","unstructured":"Hosseini-Hooshyar S, Hajarizadeh B, Bajis S, Law M, Janjua NZ, Fierer DS, Chromy D, Rockstroh JK, Martin TCS. Ingiliz P et al: risk of hepatitis C reinfection following successful therapy among people living with hiv: a global systematic review, meta-analysis, and meta-regression. Lancet HIV. 2022;9(6):e414\u201327","journal-title":"Lancet HIV"},{"issue":"8","key":"12025_CR43","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1111\/hiv.13651","volume":"25","author":"P Ingiliz","year":"2024","unstructured":"Ingiliz P, Lutz T, Schewe K, Baumgarten A, Krznaric I, Mauss S, Christensen S, Bickel M, Schmidt AJ, Sabranski M, et al. Recently acquired HCV infection in men who have sex with men in Germany in the direct-acting antivirals era and during the COVID-19 pandemic. HIV Med. 2024;25(8):967\u201375","journal-title":"HIV Med"},{"issue":"3","key":"12025_CR44","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/hep.26164","volume":"57","author":"NA Terrault","year":"2013","unstructured":"Terrault NA, Dodge JL, Murphy EL, Tavis JE, Kiss A, Levin TR, Gish RG, Busch MP, Reingold AL, Alter MJ. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology. 2013;57(3):881\u201389","journal-title":"Hepatology"},{"issue":"4","key":"12025_CR45","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3109\/00365549509032726","volume":"27","author":"K Stark","year":"1995","unstructured":"Stark K, Schreier E, M\u00fcller R, Wirth D, Driesel G, Bienzle U. Prevalence and determinants of anti-HCV seropositivity and of HCV genotype among intravenous drug users in Berlin. Scand J Infect Dis. 1995;27(4):331\u201337","journal-title":"Scand J Infect Dis"},{"issue":"6","key":"12025_CR46","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1093\/ije\/26.6.1359","volume":"26","author":"K Stark","year":"1997","unstructured":"Stark K, Bienzle U, Vonk R, Guggenmoos-Holzmann I. History of syringe sharing in prison and risk of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection among injecting drug users in Berlin. Int J Epidemiol. 1997;26(6):1359\u201366","journal-title":"Int J Epidemiol"},{"issue":"3","key":"12025_CR47","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1017\/S0950268802007902","volume":"129","author":"K Roy","year":"2002","unstructured":"Roy K, Hay G, Andragetti R, Taylor A, Goldberg D, Wiessing L. Monitoring hepatitis C virus infection among injecting drug users in the European Union: a review of the literature. Epidemiol Infect. 2002;129(3):577\u201385","journal-title":"Epidemiol Infect"},{"issue":"6","key":"12025_CR48","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1023\/A:1024603517136","volume":"18","author":"M Backmund","year":"2003","unstructured":"Backmund M, Meyer K, Wachtler M, Eichenlaub D. Hepatitis C virus infection in injection drug users in Bavaria: risk factors for seropositivity. Eur J Epidemiol. 2003;18(6):563\u201368","journal-title":"Eur J Epidemiol"},{"key":"12025_CR49","doi-asserted-by":"publisher","first-page":"104635","DOI":"10.1016\/j.drugpo.2024.104635","volume":"134","author":"MP Gunaratne","year":"2024","unstructured":"Gunaratne MP, Kedar A, McFall AM, Srikrishnan AK, Chingtham S, Amrose P, Baishya JJ, Sinha AK, Mehta SH, Solomon SS. High hepatitis C virus reinfection in a community-based sample of people who inject drugs in Imphal, India. Int J Drug Policy. 2024;134:104635","journal-title":"Int J Drug Policy"},{"issue":"1","key":"12025_CR50","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12954-020-00399-8","volume":"17","author":"B Muncan","year":"2020","unstructured":"Muncan B, Walters SM, Ezell J, Ompad DC. \u201cThey look at us like junkies\u201d: influences of drug use stigma on the healthcare engagement of people who inject drugs in New York City. Harm Reduct J. 2020;17(1):53","journal-title":"Harm Reduct J"},{"issue":"1","key":"12025_CR51","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12954-025-01166-3","volume":"22","author":"Z Papalamprakopoulou","year":"2025","unstructured":"Papalamprakopoulou Z, Ntagianta E, Triantafyllou V, Kalamitsis G, Dharia A, Dickerson SS, Hatzakis A, Talal AH. Breaking the vicious cycle of delayed healthcare seeking for people who use drugs. Harm Reduct J. 2025;22(1):27","journal-title":"Harm Reduct J"},{"issue":"5","key":"12025_CR52","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.1016\/S2468-2667(21)00013-X","volume":"6","author":"C Arum","year":"2021","unstructured":"Arum C, Fraser H, Artenie AA, Bivegete S, Trickey A, Alary M, Astemborski J, Iversen J, Lim AG, L M, et al. Homelessness, unstable housing, and risk of hiv and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. Lancet Public Health. 2021;6(5):e309\u201323","journal-title":"Lancet Public Health"},{"issue":"8\u201309","key":"12025_CR53","first-page":"712","volume":"85","author":"A Dichtl","year":"2023","unstructured":"Dichtl A, Stover H, Schaffer D. HIV\/HCV among drug users in Germany: elimination targets in the mirror of practice. Gesundheitswesen. 2023;85(8\u201309):712\u201317","journal-title":"Gesundheitswesen"},{"issue":"1","key":"12025_CR54","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12954-019-0338-y","volume":"17","author":"J Enkelmann","year":"2020","unstructured":"Enkelmann J, Gassowski M, Nielsen S, Wenz B, Ross S, Marcus U, Bremer V, Zimmermann R. Group ds: high prevalence of hepatitis C virus infection and low level of awareness among people who recently started injecting drugs in a cross-sectional study in Germany, 2011-2014. missed opportunities for hepatitis C testing. Harm Reduct J. 2020;17(1):7","journal-title":"Harm Reduct J"},{"key":"12025_CR55","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1477-7517-10-7","volume":"10","author":"M Harris","year":"2013","unstructured":"Harris M, Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors. Harm Reduct J. 2013;10:7","journal-title":"Harm Reduct J"},{"issue":"1","key":"12025_CR56","doi-asserted-by":"publisher","first-page":"32571","DOI":"10.1038\/s41598-025-18552-3","volume":"15","author":"F Heinrich","year":"2025","unstructured":"Heinrich F, Wong TLE, Graf W, Dost K, Brennecke A, Kowalski V, van Ruth V, Iwersen-Bergmann S, Hajek A, Konig HH, et al. Prevalence and risk factors of viral hepatitis and hiv among people experiencing homelessness in Germany based on a nationwide study. Sci Rep. 2025;15(1):32571","journal-title":"Sci Rep"},{"key":"12025_CR57","first-page":"3","volume":"30","author":"S Hermanns","year":"2025","unstructured":"Hermanns S, Friedsam A, Steffen G, Biallas R, Dudareva S, Zimmermann R. Epidemiologie von Hepatitis-B- und Hepatitis-C-Virusinfektionen in Deutschland im Jahr 2024 - Eine Auswertung der Meldedaten gem\u00e4\u00df Infektionsschutzgesetz. Epid Bull. 2025;30:3\u201316","journal-title":"Epid Bull"},{"issue":"3","key":"12025_CR58","first-page":"3","volume":"26","author":"U Koppe","year":"2025","unstructured":"Koppe U, Friebe M, Sch\u00f6n K, Papke B, Kollan C, Hofmann A, Schmidt D, Zimmermann R, An der Heiden M, Bremer V, et al. HIV-Jahresbericht 2024. Epid Bull. 2025;26(3):3\u201318","journal-title":"Epid Bull"},{"issue":"16","key":"12025_CR59","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1055\/a-2057-1797","volume":"149","author":"A Schmitt","year":"2024","unstructured":"Schmitt A, Sarrazin C. Hepatitis C: from diagnosis to global virus elimination. Dtsch Med Wochenschr. 2024;149(16):955\u201361","journal-title":"Dtsch Med Wochenschr"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12025-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-12025-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12025-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T16:03:15Z","timestamp":1762358595000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-12025-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12025"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-12025-8","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Robert Koch Institute is a higher federal authority within the portfolio of the German Federal Ministry of Health. According to Article 4 Paragraph 1 Infektionsschutzgesetz (IfSG; German Infection Protection Act) the Robert Koch Institute is the national authority for the prevention of communicable diseases and for the early detection and prevention of the spread of infections. The non-named notification data and associated anonymous DSS\/DPS for sentinel surveillance were provided to the Robert Koch Institute according to Articles 7 and 13 Paragraph 3 IfSG and processed by the Robert Koch Institute in line with the regulations of the IfSG. The statutory notification of new HIV diagnoses and the surveillance on which this study is based (Article 7 and 13 Paragraph 3 IfSG) do not require an informed consent or an ethical review. Ethical approval and an informed consent to participate in this study were therefore not obtained. The German Parliament as legislator of the IfSG naturally also takes ethical aspects, including the Helsinki Declaration, into account. Thus, our surveillance study adheres to the principles of the Declaration of Helsinki to this effect. The study protocol on HCV-coinfections among the notified new HIV-diagnoses and its legal basis have been approved by the internal review board and the data protection officer of the RKI. An approval for usage of DSS\/DPS prepared from residual blood of notified new HIV diagnoses for the national surveillance has also been granted by the Federal Commissioner for Data Protection and Freedom of Information (Monitoring of HIV-Infections in Germany, III-401\/008#0016).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"VB received travel expense support from the organizers of the German-Austrian AIDS Congress. She is a member of DIAG, The German STI society and the coordinating committee of the Federal government to implement the strategy to contain HIV, hepatitis B and C and other sexually transmitted infections. UK received support for attending meetings and\/or travel from ECDC, German AIDS Society, German STI Society, and European AIDS Society and also owns \u2018Exchange-traded fund\u2019 (ETF) shares, which includes stocks of companies involved in health care. All other authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1511"}}